ReviewNanomedicine (London, England)2026
Nanotechnology based targeted drug delivery systems for breast cancer: challenges, recent advancement and future perspectives.
Review in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A multifunctional hydrogel dressing for wound healing and in vitro cytotoxicity against breast cancer cells: association with GRP78 expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities.Biomedicines · 2026Review
- Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, breast cancer remains a leading causes of cancer-related mortality among women, emphasizing the need for more effective therapies. Nanotechnology-based drug delivery systems have emerged as promising tools for reducing systemic toxicity while enhancing the precision and efficacy of treatments. By engineering nanoparticles to selectively target tumor cells, these systems increase drug accumulation at the tumor site and minimize harm to healthy tissues. This review focuses on the development of nanocarrier systems such as liposomes, polymeric nanoparticles, dendrimers, micelles, metallic nanoparticles, black phosphorus, and protein-based nanoparticles for the targeted delivery of chemotherapeutic agents in breast cancer. Both passive and active targeting mechanisms were explored, including the enhanced permeability and retention (EPR) effect, tumor specific biomarkers to achieve stimuli-responsive drug release. Future directions in research aim to further optimize these nanocarriers to enhance therapeutic efficacy while minimizing toxicity. The integration of personalized medicine with smart nanocarriers, AI-assisted delivery systems, diagnostic tools, and CRISPR/Cas9 gene editing holds great promise for more precise and individualized breast cancer therapies. Despite significant progress, challenges such as regulatory hurdles, tumor heterogeneity, multidrug resistance, issues related to nanoparticle biocompatibility continue to impede clinical translation. This work also addresses these barriers and implementation of nanomedicine in clinical oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.